Skip to Content

Preclinical Data on ARIAD's Oncology Pipeline to Be Presented at the AACR Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2009 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new preclinical data on deforolimus, its investigational mTOR inhibitor, AP24534, its investigational multi-targeted kinase inhibitor, and its investigational anaplastic lymphoma kinase (ALK) inhibitor, will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado, being held April 18 to 22, 2009.

The schedule and meeting location for the sessions, together with the abstract information, are listed below:

Date & Time: Sunday, April 19, 2009, 1:00 PM - 5:00 PM
Session Title: Kinase Inhibitors 1
Abstract: #1739
Title: The orally active kinase inhibitor AP24534 has potent activity against the FGF receptor family in multiple cancer models
Presenter: Joseph M. Gozgit, Ph.D. (ARIAD Pharmaceuticals)
Location: Hall B-F, Poster Section 35, Poster Board 1

Date & Time: Sunday, April 19, 2009, 3:55 PM - 4:10 PM
Session Title: Understanding and Targeting Oncogenic Pathways
Abstract: #1887
Title: The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancer
Presenter: Brian Haines, Ph.D. (Merck & Co.)
Location: Room 502-504, Oral Presentation

Date & Time: Monday, April 20, 2009, 1:00 PM - 5:00 PM
Session Title: IGF-IR and PI3K Pathways
Abstract: #2809
Title: Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity
Presenter: Sriram Sathyanarayanan, Ph.D. (Merck & Co.)
Location: Hall B-F, Poster Section 33, Poster Board 9

Date & Time: Tuesday, April 21, 2009, 8:00 AM -12:00 PM
Session Title: Kinase Inhibitors 3
Abstract: #3738
Title: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)
Presenter: William C. Shakespeare, Ph.D. (ARIAD Pharmaceuticals)
Location: Hall B-F, Poster Section 36, Poster Board 22


ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, deforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD's second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit

Contact: ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208

Posted: April 2009